Group One Trading’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-19,000
Closed -$14K 5981
2019
Q3
$14K Buy
19,000
+14,000
+280% +$10.1K ﹤0.01% 4504
2019
Q2
$4K Buy
+5,000
New +$5.56K ﹤0.01% 4676
2018
Q4
Sell
-9,800
Closed -$29K 5759
2018
Q3
$29K Buy
+9,800
New +$34.7K ﹤0.01% 4256
2018
Q2
Sell
-1,000
Closed -$4K 5707
2018
Q1
$4K Hold
1,000
﹤0.01% 4573
2017
Q4
$3K Buy
+1,000
New +$4.81K ﹤0.01% 4668
2017
Q3
Sell
-26,500
Closed -$245K 5392
2017
Q2
$245K Buy
26,500
+25,000
+1,667% +$241K ﹤0.01% 2496
2017
Q1
$16K Sell
1,500
-15,200
-91% -$155K ﹤0.01% 3973
2016
Q4
$141K Buy
+16,700
New +$148K ﹤0.01% 2641

Other funds holding NVLN

Group One Trading's NVLN Position: Q4 2019 in Review

Group One Trading sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q4 2019, closing a stake of 52,068 shares — an estimated $38K sold.

Group One Trading first reported a position in NVLN in Q4 2016 and held it in 10 quarters. The position peaked at $106K in Q1 2017. 7 funds tracked by Wall St. Rank hold NVLN as of Q4 2019.

  • Group One Trading reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q4 2019 after selling out during the quarter.
  • Group One Trading sold 52,068 Novelion Therapeutics Inc. Common Shares shares in Q4 2019, an estimated $38K.
  • Group One Trading first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 10 quarters.
  • Group One Trading's Novelion Therapeutics Inc. Common Shares position peaked at $106K in Q1 2017.
  • 7 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q4 2019.

Based on Group One Trading's 13F filing for Q4 2019, filed 10 Feb 2020.